Neonatal group B streptococcus disease in developing countries: Are we ready to deploy a vaccine?

Pui Ying Iroh Tam, Shirley F. Delair, Stephen K Obaro

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Group B streptococcus (GBS) disease is the leading cause of neonatal sepsis in developed countries and has high case fatality rates. In developing countries, however, the burden of GBS is less clear; this is due to a lack of studies using optimal diagnostic, clinical and laboratory techniques and is complicated by the wide availability of non-prescription antibiotics to the general population and in peripartum patients. There is an urgent need for prospective, population-based surveillance to provide an accurate assessment of neonatal GBS disease burden in developing countries, which remains largely unrecognized, and consequently obscures the potential relevance of GBS vaccination in these populations. Preliminary data on GBS vaccines are promising as a preventive tool for neonatal GBS infection, more so than any other currently available public health initiative. However, how do we assess the true impact of a GBS vaccine without accurate surveillance data on the real burden of disease?

Original languageEnglish (US)
Pages (from-to)1401-1403
Number of pages3
JournalExpert Review of Vaccines
Volume14
Issue number11
DOIs
StatePublished - Nov 2 2015

Fingerprint

Streptococcus agalactiae
Developing Countries
Vaccines
Population Surveillance
Peripartum Period
Clinical Laboratory Techniques
Developed Countries
Population
Vaccination
Public Health
Anti-Bacterial Agents
Mortality
Infection

Keywords

  • Streptococcus agalactiae
  • broad-spectrum antimicrobial use
  • developing countries
  • group B streptococcus
  • intrapartum antibiotic prophylaxis
  • neonatal sepsis
  • vaccination

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Neonatal group B streptococcus disease in developing countries : Are we ready to deploy a vaccine? / Iroh Tam, Pui Ying; Delair, Shirley F.; Obaro, Stephen K.

In: Expert Review of Vaccines, Vol. 14, No. 11, 02.11.2015, p. 1401-1403.

Research output: Contribution to journalReview article

@article{a9086a5b66874e61a0886e17e7053e8b,
title = "Neonatal group B streptococcus disease in developing countries: Are we ready to deploy a vaccine?",
abstract = "Group B streptococcus (GBS) disease is the leading cause of neonatal sepsis in developed countries and has high case fatality rates. In developing countries, however, the burden of GBS is less clear; this is due to a lack of studies using optimal diagnostic, clinical and laboratory techniques and is complicated by the wide availability of non-prescription antibiotics to the general population and in peripartum patients. There is an urgent need for prospective, population-based surveillance to provide an accurate assessment of neonatal GBS disease burden in developing countries, which remains largely unrecognized, and consequently obscures the potential relevance of GBS vaccination in these populations. Preliminary data on GBS vaccines are promising as a preventive tool for neonatal GBS infection, more so than any other currently available public health initiative. However, how do we assess the true impact of a GBS vaccine without accurate surveillance data on the real burden of disease?",
keywords = "Streptococcus agalactiae, broad-spectrum antimicrobial use, developing countries, group B streptococcus, intrapartum antibiotic prophylaxis, neonatal sepsis, vaccination",
author = "{Iroh Tam}, {Pui Ying} and Delair, {Shirley F.} and Obaro, {Stephen K}",
year = "2015",
month = "11",
day = "2",
doi = "10.1586/14760584.2015.1077121",
language = "English (US)",
volume = "14",
pages = "1401--1403",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Neonatal group B streptococcus disease in developing countries

T2 - Are we ready to deploy a vaccine?

AU - Iroh Tam, Pui Ying

AU - Delair, Shirley F.

AU - Obaro, Stephen K

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Group B streptococcus (GBS) disease is the leading cause of neonatal sepsis in developed countries and has high case fatality rates. In developing countries, however, the burden of GBS is less clear; this is due to a lack of studies using optimal diagnostic, clinical and laboratory techniques and is complicated by the wide availability of non-prescription antibiotics to the general population and in peripartum patients. There is an urgent need for prospective, population-based surveillance to provide an accurate assessment of neonatal GBS disease burden in developing countries, which remains largely unrecognized, and consequently obscures the potential relevance of GBS vaccination in these populations. Preliminary data on GBS vaccines are promising as a preventive tool for neonatal GBS infection, more so than any other currently available public health initiative. However, how do we assess the true impact of a GBS vaccine without accurate surveillance data on the real burden of disease?

AB - Group B streptococcus (GBS) disease is the leading cause of neonatal sepsis in developed countries and has high case fatality rates. In developing countries, however, the burden of GBS is less clear; this is due to a lack of studies using optimal diagnostic, clinical and laboratory techniques and is complicated by the wide availability of non-prescription antibiotics to the general population and in peripartum patients. There is an urgent need for prospective, population-based surveillance to provide an accurate assessment of neonatal GBS disease burden in developing countries, which remains largely unrecognized, and consequently obscures the potential relevance of GBS vaccination in these populations. Preliminary data on GBS vaccines are promising as a preventive tool for neonatal GBS infection, more so than any other currently available public health initiative. However, how do we assess the true impact of a GBS vaccine without accurate surveillance data on the real burden of disease?

KW - Streptococcus agalactiae

KW - broad-spectrum antimicrobial use

KW - developing countries

KW - group B streptococcus

KW - intrapartum antibiotic prophylaxis

KW - neonatal sepsis

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=84945443631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945443631&partnerID=8YFLogxK

U2 - 10.1586/14760584.2015.1077121

DO - 10.1586/14760584.2015.1077121

M3 - Review article

C2 - 26289974

AN - SCOPUS:84945443631

VL - 14

SP - 1401

EP - 1403

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 11

ER -